Cardarine is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport; not approved as medicine | Listed by WADA at all times. |
| Common synonyms | GW501516, GW-501516, endurobol | Cardarine is a colloquial name. |
| Typical analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Common test matrix | Urine | Blood and dried blood spots also possible. |
| Legal classification | Varies by country | Often treated as unapproved drug or research chemical. |
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Products sold as cardarine have been found to contain incorrect compounds, variable amounts, or no active ingredient at all. Independent testing is required to verify identity and purity. Common analytical approaches include high-performance liquid chromatography, mass spectrometry, and nuclear magnetic resonance for structural confirmation. These methods can distinguish GW501516 from related PPAR agonists and from unrelated steroids. For regulators and researchers, such verification is central to interpreting both biological results and adverse event reports.
=== Names === Octodrine is the generic name of the drug and its INNTooltip International Nonproprietary Name and USANTooltip United States Adopted Name. It is also known by its former developmental code name SKF-51.
Having a mild form of alpha thalassemia has been demonstrated to protect against malaria and thus can be an advantage in malaria endemic areas, thus conferring a selective survival advantage on carriers (known as heterozygous advantage), and perpetuating the mutation. There are suggestions that mild beta thalassemia may provide similar protection but this has not been proven. α-thalassemia genes have a high prevalence in populations of sub-Saharan Africa, Mediterranean, Middle East, and southeast and east Asia. β-thalassemias are prevalent in the populations of the Mediterranean, Middle East, and Southeast Asia.
Another factor affecting the treatment response is the generation of antibodies against the infused enzyme, which is particularly severe in Pompe infants who have a complete deficiency of the acid alpha-glucosidase. Immune tolerance therapy to eliminate these antibodies has improved the treatment outcome. A Late Onset Treatment Study (LOTS) was published in 2010. The study was undertaken to evaluate the safety and efficacy of aglucosidase alfa in juvenile and adult patients with Pompe disease. LOTS was a randomized, double-blind, placebo-controlled study that enrolled 90 patients at eight primary sites in the United States and Europe. Participants received either aglucosidase alfa or a placebo every other week for 18 months. The average age of study participants was 44 years. The primary efficacy endpoints of the study sought to determine the effect of Myozyme on functional endurance as measured by the six-minute walk test and to determine the effect of aglucosidase alfa on pulmonary function as measured by percent predicted forced vital capacity. The results showed that, at 78 weeks, patients treated with aglucosidase alfa increased their distance walked in six minutes by an average of approximately 25 meters as compared with the placebo group which declined by 3 meters (P=0.03). The placebo group did not show any improvement from baseline. The average baseline distance walked in six minutes in both groups was approximately 325 meters. Percent predicted forced vital capacity in the group of patients treated with aglucosidase alfa increased by 1.2 percent at 78 weeks.
Sources: en.wikipedia.org
=== Lodotra === "Lodotra" is the brand name of an oral formulation, which releases prednisone four hours after ingestion. It is indicated for rheumatoid arthritis with morning stiffness. Taken at 10 p.m., it releases the drug at around 2 a.m. The plasmic peak level is reached at 4 a.m., which is considered to be the optimal time for relieving morning stiffness. The drug was approved in the European Union, in January 2009.
The many-worlds interpretation is discussed by high-level avout at evening meals to which Erasmas performs the duties of a servant. It is hinted that Laterre is a futuristic Earth, which serves as a 'higher plane of existence' for Urnud and Tro, and Arbre is itself a 'higher plane' for Laterre and Fthos. Through observation and experiment, Erasmas and his companions determine that the conference has been infiltrated by the aliens and unmask a French-speaking Laterran linguist named Jules Verne Durand. He explains that the aliens are experiencing internal conflict between two factions. The currently ruling faction (the more militaristic 'lower worlds' Urnud and Tro, as well as some Laterrans) intends to attack and raid Arbre for its resources in order to repair their spaceship, while the opposing faction ('the higher world' Fthos and most Laterrans) favors open negotiation. Durand believes that an alliance could be formed between Arbre and the peaceful faction and offers to help the Arbrans. Fearing alien attack after Durand has been exposed, the avout simultaneously evacuate all concents including Saunt Tredegarh. Erasmas and his comrades are taken to a distant sanctuary where they undergo astronaut training for a mission to board the alien ship, disable its weaponry and negotiate with the aliens. Prior to launch and without their knowledge, the Sæcular Power implants each of them with miniaturized neutron bombs that will be used to kill everyone aboard the alien ship if the mission fails. Three people, including Fraa Jad, are issued detonators.
== Sports == A 2017 INSEE study reported persistent gender disparities in physical and sports activities. Women were underrepresented in racket and team sports. In media coverage, women's sports accounted for less than 20% of televised sports airtime. Leadership roles in sports organizations remain limited for women. Despite the 2014 law for real gender equality, in 2019 only one Olympic sports federation and eleven non-Olympic federations were led by women.
Sources: en.wikipedia.org
For most of the Lower Paleolithic, human societies were possibly more hierarchical than their Middle and Upper Paleolithic descendants, and probably were not grouped into bands, though during the end of the Lower Paleolithic, the latest populations of the hominin Homo erectus may have begun living in small-scale (possibly egalitarian) bands similar to both Middle and Upper Paleolithic societies and modern hunter-gatherers. Middle Paleolithic societies, unlike Lower Paleolithic and early Neolithic ones, consisted of bands that ranged from 20 to 30 or 25–100 members and were usually nomadic. These bands were formed by several families. Bands sometimes joined into larger "macrobands" for activities such as acquiring mates and celebrations or where resources were abundant. By the end of the Paleolithic era (c. 10,000 BP), people began to settle down into permanent locations, and began to rely on agriculture for sustenance in many locations. Much evidence exists that humans took part in long-distance trade between bands for rare commodities (such as ochre, which was often used for religious purposes such as ritual) and raw materials, as early as 120,000 years ago in Middle Paleolithic. Inter-band trade may have appeared during the Middle Paleolithic because trade between bands would have helped ensure their survival by allowing them to exchange resources and commodities such as raw materials during times of relative scarcity (i.e. famine, drought). Like in modern hunter-gatherer societies, individuals in Paleolithic societies may have been subordinate to the band as a whole.
Unresolved complex mixture (UCM), or hump, is a feature frequently observed in gas chromatographic (GC) data of crude oils and extracts from organisms exposed to oil. The reason for the UCM hump appearance is that GC cannot resolve and identify a significant part of the hydrocarbons in crude oils. The resolved components appear as peaks while the UCM appears as a large background/platform. In non-biodegraded oils the UCM may comprise less than 50% of the total area of the chromatogram, while in biodegraded oils this figure can rise to over 90%. UCMs are also observed in certain refined fractions such as lubricating oils and references therein. In attempting to determine "the processes that regulate the fate of petroleum following release to the environment,” geochemist Christopher M. Reddy of Woods Hole Oceanographic Institution invented an application of comprehensive two-dimensional gas chromatography (GCxGC) that resolves UMPs and that he patented. As it degrades in a marine environment, oil undergoes complex transformations, producing residues composed of extremely complex organic mixtures that accumulate in such “protective environments” as fiddler crabs and marsh grass. These residues form the majority of the unresolved complex mixture (UCM) resulting from the breakdown of crude oils that GC had previously been unable to resolve but which Reddy’s novel GCxGC application has made accessible, enabling determination of “the underlying processes controlling petroleum fate” as it degrades in a marine environment.
=== Packaging === Food packaging technologies are used to extend the shelf-life of products, to stabilize food (preserve taste, appearance, and quality), and to maintain the food clean, protected, and appealing to the consumer. This can be achieved, for example, by packaging food in cans and jars. Because food production creates large amounts of waste, many companies are transitioning to eco-friendly packaging to preserve the environment and attract the attention of environmentally conscious consumers. Some types of environmentally friendly packaging include plastics made from corn or potatoes, bio-compostable plastic and paper products which disintegrate, and recycled content. Even though transitioning to eco-friendly packaging has positive effects on the environment, many companies are finding other benefits, such as reducing excess packaging material, helping to attract and retain customers, and showing that companies care about the environment.
Dershowitz's campaign to acquit von Bülow was assisted by Jim Cramer and future New York attorney general and governor Eliot Spitzer, who were then Harvard Law School students. Dershowitz and his team focused on the discovery of the bag containing the syringes and insulin. Sunny's family had hired a private investigator to look into her coma. The private investigator, Edwin Lambert (an associate of the Bülows' lawyer Richard Kuh), was told by several family members and a maid that Claus had recently been seen locking a closet in the Newport home that previously was always kept open. The family hired a locksmith to drive to the mansion, with the intention of picking the closet lock to find what the closet contained. They had lied to the locksmith and told him that one of them owned the house. When the three arrived, the locksmith insisted that they try again to find the key, and after some searching, Kuh found a key in von Bülow's desk that unlocked the closet. At this point, according to the three men in the original interviews, the locksmith was paid for the trip and left before the closet was actually opened, although the men would later recant that version and insist that the locksmith was present when they entered the closet. It was in the closet that the main evidence against von Bülow was found. In 1984, the two convictions from the first trial were reversed by the Rhode Island Supreme Court. In 1985, after a second trial, von Bülow was found not guilty on all charges.
Sources: en.wikipedia.org
Legal status varies by country. It is not approved as a medicine, and it is prohibited in sport. Some jurisdictions restrict import, sale, or possession.
Laboratories use liquid chromatography-tandem mass spectrometry to detect GW501516 and its metabolites. Urine is commonly tested, and testing can occur in and out of competition.
No, cardarine is not a SARM. It is a PPARδ agonist, which acts on a different receptor. The two classes are often confused in online discussions.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.